Blencowe Resources: Aspiring to become one of the largest graphite producers in the world. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,799.50
Bid: 1,796.00
Ask: 1,796.50
Change: 19.00 (1.07%)
Spread: 0.50 (0.028%)
Open: 1,784.00
High: 1,799.50
Low: 1,780.00
Prev. Close: 1,780.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: Haleon reports double-digit revenue growth

Tue, 20th Sep 2022 07:51

(Alliance News) - Stocks in London are set to open higher on Tuesday, as markets in London return to action following a bank holiday for the state funeral of Queen Elizabeth II.

Markets this week will be focused on major central bank decision, with the US Federal Reserve scheduled for Wednesday and the Bank of England on Thursday, among others.

In China on Tuesday, the nation's central bank left its benchmark lending rate unchanged, in line with market expectations.

The People's Bank of China held its one-year loan prime rate - which serves as a benchmark for corporate loans - at 3.65%, while the five-year rate remained at 4.3%.

Australia's central bank on Tuesday said it expects to implement more interest rate hikes, but sees the case for a slower pace of increase as it seeks to keep the economy on "an even keel" while fighting inflation, minutes from its latest meeting showed.

The Reserve Bank of Australia increased the cash rate target earlier in September by half a percentage point to stand at 2.35% from 1.85% previously. This was the central bank's fourth consecutive 50 basis point rate hike since June.

Headlining UK company updates early Tuesday, GSK-spinoff Haleon reported double-digit revenue growth in the first half of the year.

Here is what you need to know ahead of the London market open:

----------

MARKETS

----------

FTSE 100: called up 0.6% at 7,281.40

----------

Hang Seng: up 1.1% at 18,761.66

Nikkei 225: closed up 0.4% at 27,688.42

S&P/ASX 200: closed up 1.3% at 6,806.40

----------

DJIA: closed up 197.26 points, or 0.6%, at 31,019.68

S&P 500: closed up 26.56 points, or 0.7%, at 3,899.89

Nasdaq Composite: closed up 86.62 points, or 0.8%, at 11,535.02

----------

EUR: up at USD1.0035 (USD1.0025)

GBP: up at USD1.1444 (USD1.1431)

USD: up at JPY143.30 (JPY142.93)

Gold: down at USD1,673.68 per ounce (USD1,677.01)

Oil (Brent): flat at USD92.29 a barrel (USD92.24)

(changes since previous London equities close)

----------

ECONOMICS

----------

Tuesday's key economic events still to come:

1000 CEST EU balance of payments

0830 EDT US housing starts

0855 EDT US Johnson Redbook retail sales index

1630 EDT US API Weekly statistical bulletin

----------

Producer price inflation in Germany accelerated to another record high in August, data from the Federal Statistics Office showed. In August, the producer price index increased by 45.8% compared to the same month a year prior, compared to a 37.2% increase in July, and well above consensus market expectations of a 37.5% hike, according to FXStreet. On a monthly basis, the producer price index rose by 7.9% in August from July, also a record and compared to a 5.3% rise in July from June. The acceleration was due to energy prices, which more than doubled as a result of strong rises electricity and natural gas prices.

----------

UK Prime Minister Liz Truss is committing to spend at least GBP2.3 billion next year on military aid to help Ukraine fend off Vladimir Putin's invasion. Truss pledged the UK will match or exceed the record support given to Volodymyr Zelensky's "inspirational" troops. Truss announced the support as she prepared to fly to New York, where she will use a United Nations summit in the US to rally support in helping Ukraine fight Russia. She will also try to rally world leaders to end energy dependence on Mr Putin's gas as he turns the taps off on the Nord Stream 2 pipeline.

----------

Truss has conceded that negotiations for a post-Brexit free trade deal with the US will not restart for years as she flew to New York ahead of a meeting with Joe Biden. The UK prime minister stressed her trade priority is striking agreements with India and the Gulf states, and joining a trade pact with nations including Australia and Japan. But she heavily downplayed the chances of talks even resuming to get the comprehensive deal with the States that was billed by Brexit backers as a major benefit of leaving the EU during the referendum.

----------

BROKER RATING CHANGES

----------

HSBC cuts Ocado to 'reduce' from 'hold'

----------

Credit Suisse raises Pennon to 'neutral' from 'underperform'

----------

JPMorgan places SSE on 'positive catalyst watch'

----------

COMPANIES - FTSE 100

----------

Consumer healthcare firm Haleon, in its first earnings report since being split from GSK and separately listed, reported a strong performance in the first half of 2022, noting double-digit revenue growth during the period. In the first half it reported a pretax profit of GBP864 million and revenue of GBP5.18 billion. The previous year, pretax profit totalled GBP736 million on revenue of GBP4.58 billion. Whilst noting current macro-economic challenges and uncertainties, Haleon said the positive momentum seen in the first half has continued into the second half of the year. Haleon said it is confident it is well positioned to deliver on guidance this year. Full-year revenue growth is expected between 6% and 8%.

----------

Pharmaceutical firm AstraZeneca said Evusheld, a Covid-19 treatment, has been approved in the EU for the treatments of adults and children aged 12 and over who do not require supplemental oxygen. The approval was based on results from the Tackle Phase III Covid-19 treatment trial which showed Evusheld provided clinically and statistically significant protection against progression to severe Covid-19 death against a placebo.

----------

DIY retailer Kingfisher said it delivered a first-half performance in line with expectations, while facing strong comparatives from the prior year as well as a more challenging environment. Sales in the six months that ended July 31 totalled GBP6.81 billion, down 4.1% from GBP7.10 million a year previous. Pretax profit totalled GBP474 million, down 30% against GBP677 million. Kingfisher said it had seen an "encouraging" start to trading in the second half of the year.

----------

COMPANIES - FTSE 250

----------

Online greeting card and gifting platform Moonpig said its overall trading performance from May was been in line with expectations. As a result, the firm reiterated its full-year guidance. It explained it has prioritised card sales, which have a "demonstrable track record" of resilience. Moonpig said average order values in the period have increased year-on-year and margins have remained "resilient in the absence of any significant pressure from input cost inflation".

----------

Iron ore producer Ferrexpo said has received a negative judgement from an appeal court in Ukraine regarding a claim made to invalidate a share purchase agreement from 2002 in respect of a 40% stake in Ferrexpo Poltava Mining. The court has ruled the agreement is invalid and thus the stake in Ferrexpo Poltava Mining will be transferred to the unnamed claimants. Ferrexpo said it has "compelling arguments" to defend its position.

----------

OTHER COMPANIES

----------

Healthcare software firm Craneware more than doubled its revenue in the year ended June 30. Revenue rose to USD165.5 million from USD75.6 million in the previous year. Pretax profit remained broadly flat at USD13.1 million, compared to USD13.2 million, due to amortisation of acquired intangibles and bank interest payments from the Sentry Data Systems acquisition. The firm proposed a final dividend of 15.5 pence per share, unchanged from the previous year, taking its full-year payout to 28p, up from 27.5p. Looking ahead, Craneware said it expects continued sales momentum across the group.

----------

Software developer Alfa Financial Software increased its expectations for the full-year thanks to improved contractual certainty and strong trading since its half-year results announcement at the start of September. Alfa explained it achieved improved contractual certainty with two clients, as well as request for additional people on other projects. In addition, it noted that its performance in August was "very strong" with chargeable days at a "record level".

----------

By Heather Rydings; heatherrydings@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.